Vertex Pharmaceuticals

We live in a world that relies on data. Data is used to inform everything from our hiring practices, to our building and lab designs, our clinical development programs and even the color choices for our medicines. The ability to harness this data in a creative, effective and ethical way is imperative for businesses across…

Ameritas Advisory Services LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 335 shares of the pharmaceutical company's stock, valued at approximately $107,000. A number of other…

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen analysts that are currently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month…

Reynders McVeigh Capital Management LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 178.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,972 shares of the pharmaceutical company's stock after buying an additional 2,547 shares during…

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is set to post its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Vertex Pharmaceuticals to post earnings of $3.48 per share for the quarter. Vertex Pharmaceuticals has set its FY 2023 guidance at EPS.Individual that wish to listen to the company's earnings…

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price target lifted by analysts at Bank of America from $350.00 to $400.00 in a research report issued on Friday, FlyOnTheWall reports. Bank of America's target price suggests a potential upside of 10.55% from the stock's current price. A number of other equities analysts have…

Source: luchschenF / Shutterstock.com When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes.   And in 2023, many companies are closer than ever…

Artificial intelligence (AI ) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks. I asked ChatGPT which biotech stocks it recommends for investment in July and it provided the…

Investing in the biotech sector is mostly about risk and reward. When a company achieves FDA approval on a drug or therapeutic, it frequently has a source of revenue and profit that can last for years. And investors who buy and hold these stocks are typically rewarded with handsome total returns. Even penny stocks can…

Investing in the biotech sector is mostly about risk and reward. When a company achieves FDA approval on a drug or therapeutic, it frequently has a source of revenue and profit that can last for years. And investors who buy and hold these stocks are typically rewarded with handsome total returns. Even penny stocks can…

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) have received a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among analysts…

J2 Capital Management Inc purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Rating) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,176 shares of the pharmaceutical company's stock, valued at approximately $371,000. Several other institutional investors have also recently made…